Ampyra and Scab - a phase IV clinical study of FDA data

Summary:

Scab is reported as a side effect among people who take Ampyra (dalfampridine), especially for people who are female, 50-59 old, have been taking the drug for 2 - 5 years also take Vitamin B12, and have Gait disturbance.

The phase IV clinical study analyzes which people have Scab when taking Ampyra. It is created by eHealthMe based on reports of 76,998 people who have side effects when taking Ampyra from the FDA, and is updated regularly.

What is Ampyra?

Ampyra has active ingredients of dalfampridine. It is often used in multiple sclerosis. eHealthMe is studying from 77,145 Ampyra users. Check the latest studies of Ampyra.

What is Scab?

Scab (a hard coating on the skin formed during the wound healing) is found to be associated with 839 drugs and 1,081 conditions by eHealthMe. Check the latest studies of Scab.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

76,998 people reported to have side effects when taking Ampyra.
Among them, 25 people (0.03%) have Scab.

Among these 25 people:

How long have people been on Ampyra when they have Scab? *

What is the gender of people who have Scab when taking Ampyra? *

female: 76 %
male: 24 %

What is the age of people who have Scab when taking Ampyra? *

What are other drugs people take besides Ampyra? *

What are other side effects people have besides Scab? *

Balance Disorder: 11 people, 44.00%
Gait Disturbance: 8 people, 32.00%
Insomnia (sleeplessness): 7 people, 28.00%
Rashes (redness): 7 people, 28.00%
Drug Ineffective: 6 people, 24.00%
Nausea (feeling of having an urge to vomit): 6 people, 24.00%
Weakness: 6 people, 24.00%
Fall: 6 people, 24.00%
Pain: 5 people, 20.00%
Pain In Extremity: 5 people, 20.00%

What are the existing conditions these people have? *

Gait Disturbance: 9 people, 36.00%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 12.00%
Limb Discomfort (discomfort in leg): 3 people, 12.00%
Infection: 3 people, 12.00%
Stress And Anxiety: 1 person, 4.00%
Sleep Disorder: 1 person, 4.00%
Restless Leg Syndrome (a powerful urge to move your legs): 1 person, 4.00%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 1 person, 4.00%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 4.00%
Hypersensitivity: 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Ampyra and have Scab?

- Check whether Scab is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ampyra:

Ampyra (77,145 reports)

Scab treatments and more:

Scab (12,679 reports)

Browse all side effects of Ampyra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Scab:

Scab (839 drugs)

Browse all the conditions that are associated with Scab:

Scab (1,081 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Ampyra) and Ampyra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.